{"ticker": {"uuid": "9bcc773b-55ac-4a91-9274-677ac26928d5", "symbol": "TELO", "name": "Telomir Pharmaceuticals, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Telomir Pharmaceuticals, Inc. \u2013 NASDAQ:TELO", "summary": "This article provides information about the number of shareholders for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). It indicates that the company's market was closed with no trades at the time of the report. The content mentions that the data is provided by various financial ser", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-06T07:43:05", "published_display": "06 Jul 2026 07:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Telomir Pharmaceuticals, Inc. \u2013 NASDAQ:TELO", "summary": "This article provides limited financial information for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), specifically mentioning its \"Price to earnings forward\" metric. The displayed content, however, appears to be a stub or a section of a larger financial data service, showing only", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:21", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TELO)", "summary": "This article provides financial actuals and estimates for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), including its current stock price, historical performance, analyst forecasts, and upcoming earnings dates. It also covers market capitalization, volatility, and general investme", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:53", "published_display": "26 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Telomir Pharmaceuticals, Inc. \u2013 NASDAQ:TELO", "summary": "This article provides the \"Price to sales forward\" financial metric for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). It lists the company's stock exchange as Nasdaq Stock Market and indicates that the market is currently closed with no trades. The period and value for the price ", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:56", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Telomir Pharmaceuticals, Inc. \u2013 NASDAQ:TELO", "summary": "This article focuses solely on presenting the \"Enterprise value to EBITDA forward\" metric for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). The content provided is minimal, primarily indicating the company's stock market listing and that the market is currently closed with no tra", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:10:01", "published_display": "26 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Telomir Pharmaceuticals Inc (TELO), highlighting its current price momentum score of 4.57 and its position relative to support and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, which c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/technical", "source_name": "TradingKey", "published_at": "2026-06-24T16:10:56", "published_display": "24 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey reports on Telomir Pharmaceuticals Inc (TELO), noting that relevant data regarding its revenue breakdown by business segments and region, as well as profit contribution, has not yet been disclosed by the company. The article provides basic stock infor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/revenue", "source_name": "TradingKey", "published_at": "2026-06-20T07:41:10", "published_display": "20 Jun 2026 07:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Telomir Pharmaceuticals Inc (TELO), noting its current valuation score of 6.91, which ranks 143 out of 157 in the Pharmaceuticals industry. The company's P/E ratio is reported as -4.39, significantly below its recent high, while relev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T03:11:00", "published_display": "19 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Telomir Pharmaceuticals Inc (TELO)'s institutional confidence based on shareholder activity. It lists key institutional shareholders and changes in their shareholdings, showing that some major holders like Bay Shore Trust and M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:17", "published_display": "18 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Telomir Pharmaceuticals Inc (TELO) currently has no earnings forecast score available from TradingKey, with the Pharmaceuticals industry average being 7.84. Analysts forecast a price target of USD 15.50 for TELO. The company's EPS for the previous quarter was USD -0.06, against a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:01", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Telomir Pharmaceuticals Inc (TELO), noting its robust financial status but low operating efficiency, with a current financial score of 6.88. The analysis highlights that relevant financial data for various metrics like profitability, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:17", "published_display": "18 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model", "summary": "Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy, showcasing Telomir-Zn's ability to restore insulin sensitivity and improve glucose homeostasis in a zebrafish model of Type 2 diabetes. The study demonstrated sig", "url": "https://www.dailycorinthian.com/news/national/telomir-pharmaceuticals-announces-peer-reviewed-publication-in-biomedicine-pharmacotherapy-demonstrating-restoration-of-insulin-sensitivity-with/article_d0576d42-c84b-5f4d-883f-9538a665c95a.html", "source_name": "The Daily Corinthian", "published_at": "2026-06-16T00:10:53", "published_display": "16 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir publishes preclinical data on diabetes treatment candidate", "summary": "Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for its compound Telomir-Zn, which showed restoration of insulin sensitivity in a zebrafish model of Type 2 diabetes. Despite a 36% share decline over the past year, the clinical-stage biotech com", "url": "https://www.investing.com/news/company-news/telomir-publishes-preclinical-data-on-diabetes-treatment-candidate-93CH-4742018", "source_name": "Investing.com", "published_at": "2026-06-15T12:09:42", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir publishes preclinical data on diabetes treatment candidate By Investing.com", "summary": "Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for its compound Telomir-Zn, demonstrating its ability to restore insulin sensitivity in a zebrafish model of Type 2 diabetes. Despite a 36% share decline over the past year, the company, with a $", "url": "https://ca.investing.com/news/stock-market-news/telomir-publishes-preclinical-data-on-diabetes-treatment-candidate-93CH-4690699", "source_name": "Investing.com Canada", "published_at": "2026-06-15T12:09:08", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental drug candidate reversed insulin resistance in 14 days \u2014 in fish", "summary": "Telomir Pharmaceuticals announced that its experimental drug candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a preclinical zebrafish model of Type 2 diabetes. The peer-reviewed study, published in Biomedicine & Pharmacotherapy, showed a sig", "url": "https://www.stocktitan.net/news/TELO/telomir-pharmaceuticals-announces-peer-reviewed-publication-in-2vxfo4c2s1r1.html", "source_name": "Stock Titan", "published_at": "2026-06-15T12:09:08", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial", "summary": "Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data for its lead program, Telomir-Zn, published in Biomedicine & Pharmacotherapy. The study showed that Telomir-Zn improved glucose metabolism and insulin resistance in a zebrafish model of Type 2 diabetes, normali", "url": "https://www.stocktitan.net/sec-filings/TELO/8-k-telomir-pharmaceuticals-inc-reports-material-event-0ae3713e8782.html", "source_name": "Stock Titan", "published_at": "2026-06-15T12:09:07", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change", "summary": "Telomir Pharmaceuticals (TELO) has appointed Andriy Mushak as its fractional Chief Financial Officer through a consulting arrangement with LMAM Consulting Group, following the departure of Alan Weichselbaum. Mushak, a CPA with over 20 years of SEC reporting and audit experience, ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TELO-Q/pressreleases/2389038/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change/", "source_name": "The Globe and Mail", "published_at": "2026-06-11T13:09:17", "published_display": "11 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Cash Burn Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPU1FvM1BvSDE5a0dqQzdUTUFTbWhZWmhnaUNVR1JqTGtyaTdHektINDlpV1Y5d3FNQXhvUTNLMklCV2Y5d3U3YWQwSTZCQ3RPV2o1akw5STNqRk9BN2I0VUdFMzU1T0JJbVR2aEwyamJ0cVFYUVBCYS04WHNFOW16c2djbUJpRDNya21WbkVPaUNfOHJibFE4R1k2d2tIMUV2UnNILTc5bWxFRnRXeHlGcDUzYURhYllfa0JpMEs5UGdZQURmWk9tUDI0eHJuMVhNYW5Faw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Cash Burn Concerns - Consensus Miss Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOb0E2SEh1dXFQU0FJdkl0SG55dERKR0JPOWNPM3V4R3RSOTAwSDROQ1dnS2lWbW5GMlA2YkxYRzI3VG5QS3hKQ3lweWtmSVVrSHgyTU1NNG45TFNacGRBeHpMME56WVpxTDl3TU5QUnNoc0dLQXczcVVaTTNJbHdhTXFkMUFlU0tDRkxrZWMycFhZYndKYmNUek45QzQtR3dDZVVTN2h2dHJOd1RnMWRCOVZmQVVEVVhRb3l3VHZ5T3pydm9jNDZzSl9UMnRUazZNSlJ3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO", "summary": "Telomir Pharmaceuticals has appointed Andriy Mushak as its fractional Chief Financial Officer, effective June 6, following the departure of Alan Weichselbaum. Mushak brings over 20 years of experience in SEC reporting and accounting, and will provide his services through a consul", "url": "https://m.uk.investing.com/news/sec-filings/telomir-pharmaceuticals-appoints-andriy-mushak-as-fractional-cfo-93CH-4718510?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-09T23:09:23", "published_display": "09 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3", "summary": "Telomir Pharmaceuticals (TELO) Chief Financial Officer Andriy Mushak has filed an initial Form 3, an SEC filing that reports his status as an officer. The filing indicates that Mushak does not currently hold any common stock or derivative securities in the company. This Form 3 ac", "url": "https://www.stocktitan.net/sec-filings/TELO/form-3-telomir-pharmaceuticals-inc-initial-statement-of-beneficial-ow-0ed194fcdb51.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:39:39", "published_display": "09 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Names Andriy Mushak as Fractional Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/telomir-names-andriy-mushak-fractional-120714089.html", "source_name": "MT Newswires", "published_at": "2026-06-09T12:07:14+00:00", "published_display": "09 Jun 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com", "summary": "Telomir Pharmaceuticals has appointed Andriy Mushak as its fractional Chief Financial Officer, effective June 6, following Alan Weichselbaum's departure. Mushak, a partner at LMAM Consulting Group, brings over two decades of experience in SEC reporting and accounting. The company", "url": "https://za.investing.com/news/sec-filings/telomir-pharmaceuticals-appoints-andriy-mushak-as-fractional-cfo-93CH-4318895", "source_name": "Investing.com South Africa", "published_at": "2026-06-08T22:39:17", "published_display": "08 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing", "summary": "Telomir Pharmaceuticals announced through an SEC filing that Alan Weichselbaum will step down from his position as CFO, effective June 6, 2026. This brief notice was disseminated via Reuters and is directly related to an SEC filing. The company's stock symbol is TELO.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42G0Z0:0-telomir-pharmaceuticals-alan-weichselbaum-to-step-down-as-cfo-effective-june-6-2026-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-08T21:10:43", "published_display": "08 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO", "summary": "Telomir Pharmaceuticals announced a change in its finance leadership, appointing Andriy Mushak as the new fractional Chief Financial Officer through LMAM Consulting Group, LLC. This follows the departure of Alan Weichselbaum, which the company states was not due to any disagreeme", "url": "https://www.stocktitan.net/sec-filings/TELO/8-k-telomir-pharmaceuticals-inc-reports-material-event-97e9524a656f.html", "source_name": "Stock Titan", "published_at": "2026-06-08T21:10:43", "published_display": "08 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026", "summary": "Telomir Pharmaceuticals, Inc. announced a change in its Chief Financial Officer position, effective June 6, 2026. Alan Weichselbaum is no longer serving as CFO, and Andriy Mushak has been appointed as the Company's fractional Chief Financial Officer. Mr. Mushak is a Certified Pub", "url": "https://www.marketscreener.com/news/telomir-pharmaceuticals-inc-announces-cfo-changes-effective-june-6-2026-ce7f5dd3df8ef125", "source_name": "www.marketscreener.com", "published_at": "2026-06-08T21:10:43", "published_display": "08 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TELO - Telomir Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data and recent news for Telomir Pharmaceuticals Inc (TELO). It details the company's stock performance, key financial metrics, insider ownership, and institutional transactions. The latter part of the article highlights numerous anno", "url": "https://finviz.com/stock?t=TELO", "source_name": "Finviz", "published_at": "2026-05-30T18:12:01", "published_display": "30 May 2026 18:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TELO Stock Price, Quote & Chart | TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO)", "summary": "This article provides a comprehensive overview of TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO) stock, including its current price, performance metrics, and key statistics. It also details the company's technical and fundamental analysis ratings from ChartMill, future earnings dates,", "url": "https://www.chartmill.com/stock/quote/TELO/profile", "source_name": "ChartMill", "published_at": "2026-05-27T04:08:41", "published_display": "27 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider Than Expected Loss Highlights Pre-Revenue Challenges - Dividend Cut Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxONTJDemhDTVdhYmMwZTEyc19UbDFRUGFWRGNjMkxtS2lSY2ZnTVFFSEM0UWY4WG1yaEtaLVNDQ0c3cWFWRVM5NTByMlYtV0lUZ2FkZERoNEk2LTd1a1lSb3hJSTdDMUV5ZS1zV244Y3dPRDNNMEtZSm56bC1QUDFZLWJGOXlvRXNzNlNBXy1aeGhOa0FVTmdfb3ZaM3F3LWJ5SkR1em9zNk5BLU5KV3lVUzBFUmFTb3JURm8xcHBkUnoxbzJOTnMtTkFBMUxuaW5oYUdiZjQ3a1BLWmlTN3FUVVVva08xaFk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir (TELO) director swaps 25K options for new lower-priced grant", "summary": "Telomir Pharmaceuticals director Edward Clouston MacPherson restructured his stock options by canceling an existing grant of 25,000 shares with a $5.02 exercise price and replacing it with a new 25,000-share option at a lower exercise price of $1.30. This transaction, revealed in", "url": "https://www.stocktitan.net/sec-filings/TELO/form-4-telomir-pharmaceuticals-inc-insider-trading-activity-5a2170ba0f4d.html", "source_name": "Stock Titan", "published_at": "2026-05-23T01:39:54", "published_display": "23 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir (NASDAQ: TELO) CEO reshapes 4M+ options at lower $1.30 strike", "summary": "Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov recently modified his stock option awards. He canceled previously granted options totaling nearly 4 million shares at higher exercise prices ($2.10 and $5.02) and received new, fully exercisable options for the same numbe", "url": "https://www.stocktitan.net/sec-filings/TELO/form-4-telomir-pharmaceuticals-inc-insider-trading-activity-19c98654bd8a.html", "source_name": "Stock Titan", "published_at": "2026-05-23T00:10:12", "published_display": "23 May 2026 00:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/telomir-pharmaceuticals-reports-peer-reviewed-120000295.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/telomir-says-us-fda-clears-142611361.html", "source_name": "MT Newswires", "published_at": "2026-04-30T14:26:11+00:00", "published_display": "30 Apr 2026 14:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/telomir-pharmaceuticals-announces-fda-clearance-120000413.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-30T12:00:00+00:00", "published_display": "30 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxON21md2NtM05RZTV3ZkNtY0xpd2tjZlREWEhxb0xNMFgyVHJwQk1seU4zcThUOFBONjRPcVR5SzdCUndqZ0xGbThIeGtQaXFNRWhhMHFKT3d3dVc4RERSUW56eW9xQXJvUlhsOUgwUFVXcWhHZkpfSFNRcHJvR29xUHNBaEhiMk1tOGlPSm9RMnUxaTR0V1A0WTEzYmk3ZnpjSnJCMEppYVJZVDJ0SkV5RFg3a29Lam1iOE9yZERJalNqRUVDc200T0l0R0ZkZEd5R0hNVTlMTmV6MGtpakE5cFNSZ0k?oc=5", "source_name": "ACCESS Newswire", "published_at": "2026-04-24T13:04:25+00:00", "published_display": "24 Apr 2026 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir completes acquisition of TELI Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQSldNNW1ZZThwVlhwejZMZURQekc5ajJKTEZVSVRKSTJ2b0I0d0hyRVNBUlN4d3J0ZHFSR210UnlIOTRoWEtjekQ3UGJxNi1uOUs1LU1Kbm84Z2xCU0l1QmYzSVk1NVo3enlWTTc0VHB3RE5jV1liMTRGVlNDWU05Wlo5ZkVpRmNLOF9NUG1JYW9iLXFBajBTaVBPdWNGYVZZUWNlY1FsVS00MERtSE1z?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQYXJ4ZldVWG9DY2VDd08wMUhHOXdlaTNhYmdyOGhIeUV2Xy1BUFRaOWFEZlBmd1ozTGlVbnJ4Zmp6SDFEZmVvbm5BWVJ6NC16YkZCNEk3NElISzlaN2swYlgxeDBvWFJvR0tOd3poRVVUMmxRVEd1ZjFyeV9GYTJvVzFiQmlwOVhSdENZWURNdWxQaVU3MmJCX2JEcUljaE02VTZkcm0wLWgzcHJUSUhoZFgwRlNhQzN6eXdrUnJhWU5BUHNFbHd2ZHA0bUxtZ01xQ3p2UXI5UHpoYkVVUTY4N1RqU0E?oc=5", "source_name": "ACCESS Newswire", "published_at": "2026-03-31T12:03:01+00:00", "published_display": "31 Mar 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgJBVV95cUxQZFNNVU1oNUNZZ1lLUmJ4cjVqbGRCWlYzTGlvTEg0Q04yZ0Q2UHRHc0U1SjdFbnNTSWR0d0FBZ3k4Q21tbG1yQTBaa29mSElTbFRZcFQwRWx0aGZSTTktUlNmeXI5ZjRRVlJMckJxaFhncVVRajc1MUNxTFBTMHQxSk5vNnRoZ3lUU21nWnN3dHNlVFM1c0FSSWJ4UmRXVkNmMnRyUjV6cGJ3bFkyUFBUTndjS1VsaHdJLW94UnBaRnkzU0ZwVUo4T1VEdzZxLUtrcjc5Q2tEU0dRZ1VYLVRoLTNGU0lWRUFTMVg1OFJ0cDFDeUtfQVZ1NDJxUF9hMHhIQUJ4cUR3?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Telomir Pharmaceuticals, Inc. \u2013 NASDAQ:TELO", "summary": "This article provides information about the number of shareholders for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). It indicates that the company's market was closed with no trades at the time of the report. The content mentions that the data is provided by various financial ser", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-06T07:43:05", "published_display": "06 Jul 2026 07:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Telomir Pharmaceuticals, Inc. \u2013 NASDAQ:TELO", "summary": "This article provides limited financial information for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), specifically mentioning its \"Price to earnings forward\" metric. The displayed content, however, appears to be a stub or a section of a larger financial data service, showing only", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:21", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TELO)", "summary": "This article provides financial actuals and estimates for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), including its current stock price, historical performance, analyst forecasts, and upcoming earnings dates. It also covers market capitalization, volatility, and general investme", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:53", "published_display": "26 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Telomir Pharmaceuticals, Inc. \u2013 NASDAQ:TELO", "summary": "This article provides the \"Price to sales forward\" financial metric for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). It lists the company's stock exchange as Nasdaq Stock Market and indicates that the market is currently closed with no trades. The period and value for the price ", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:56", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Telomir Pharmaceuticals, Inc. \u2013 NASDAQ:TELO", "summary": "This article focuses solely on presenting the \"Enterprise value to EBITDA forward\" metric for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). The content provided is minimal, primarily indicating the company's stock market listing and that the market is currently closed with no tra", "url": "https://www.tradingview.com/symbols/NASDAQ-TELO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:10:01", "published_display": "26 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Telomir Pharmaceuticals Inc (TELO), highlighting its current price momentum score of 4.57 and its position relative to support and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, which c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/technical", "source_name": "TradingKey", "published_at": "2026-06-24T16:10:56", "published_display": "24 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey reports on Telomir Pharmaceuticals Inc (TELO), noting that relevant data regarding its revenue breakdown by business segments and region, as well as profit contribution, has not yet been disclosed by the company. The article provides basic stock infor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/revenue", "source_name": "TradingKey", "published_at": "2026-06-20T07:41:10", "published_display": "20 Jun 2026 07:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Telomir Pharmaceuticals Inc (TELO), noting its current valuation score of 6.91, which ranks 143 out of 157 in the Pharmaceuticals industry. The company's P/E ratio is reported as -4.39, significantly below its recent high, while relev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T03:11:00", "published_display": "19 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Telomir Pharmaceuticals Inc (TELO)'s institutional confidence based on shareholder activity. It lists key institutional shareholders and changes in their shareholdings, showing that some major holders like Bay Shore Trust and M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:17", "published_display": "18 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Telomir Pharmaceuticals Inc (TELO) currently has no earnings forecast score available from TradingKey, with the Pharmaceuticals industry average being 7.84. Analysts forecast a price target of USD 15.50 for TELO. The company's EPS for the previous quarter was USD -0.06, against a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:01", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Telomir Pharmaceuticals Inc (TELO), noting its robust financial status but low operating efficiency, with a current financial score of 6.88. The analysis highlights that relevant financial data for various metrics like profitability, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-telo/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:17", "published_display": "18 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model", "summary": "Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy, showcasing Telomir-Zn's ability to restore insulin sensitivity and improve glucose homeostasis in a zebrafish model of Type 2 diabetes. The study demonstrated sig", "url": "https://www.dailycorinthian.com/news/national/telomir-pharmaceuticals-announces-peer-reviewed-publication-in-biomedicine-pharmacotherapy-demonstrating-restoration-of-insulin-sensitivity-with/article_d0576d42-c84b-5f4d-883f-9538a665c95a.html", "source_name": "The Daily Corinthian", "published_at": "2026-06-16T00:10:53", "published_display": "16 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir publishes preclinical data on diabetes treatment candidate", "summary": "Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for its compound Telomir-Zn, which showed restoration of insulin sensitivity in a zebrafish model of Type 2 diabetes. Despite a 36% share decline over the past year, the clinical-stage biotech com", "url": "https://www.investing.com/news/company-news/telomir-publishes-preclinical-data-on-diabetes-treatment-candidate-93CH-4742018", "source_name": "Investing.com", "published_at": "2026-06-15T12:09:42", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir publishes preclinical data on diabetes treatment candidate By Investing.com", "summary": "Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for its compound Telomir-Zn, demonstrating its ability to restore insulin sensitivity in a zebrafish model of Type 2 diabetes. Despite a 36% share decline over the past year, the company, with a $", "url": "https://ca.investing.com/news/stock-market-news/telomir-publishes-preclinical-data-on-diabetes-treatment-candidate-93CH-4690699", "source_name": "Investing.com Canada", "published_at": "2026-06-15T12:09:08", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental drug candidate reversed insulin resistance in 14 days \u2014 in fish", "summary": "Telomir Pharmaceuticals announced that its experimental drug candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a preclinical zebrafish model of Type 2 diabetes. The peer-reviewed study, published in Biomedicine & Pharmacotherapy, showed a sig", "url": "https://www.stocktitan.net/news/TELO/telomir-pharmaceuticals-announces-peer-reviewed-publication-in-2vxfo4c2s1r1.html", "source_name": "Stock Titan", "published_at": "2026-06-15T12:09:08", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial", "summary": "Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data for its lead program, Telomir-Zn, published in Biomedicine & Pharmacotherapy. The study showed that Telomir-Zn improved glucose metabolism and insulin resistance in a zebrafish model of Type 2 diabetes, normali", "url": "https://www.stocktitan.net/sec-filings/TELO/8-k-telomir-pharmaceuticals-inc-reports-material-event-0ae3713e8782.html", "source_name": "Stock Titan", "published_at": "2026-06-15T12:09:07", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change", "summary": "Telomir Pharmaceuticals (TELO) has appointed Andriy Mushak as its fractional Chief Financial Officer through a consulting arrangement with LMAM Consulting Group, following the departure of Alan Weichselbaum. Mushak, a CPA with over 20 years of SEC reporting and audit experience, ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TELO-Q/pressreleases/2389038/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change/", "source_name": "The Globe and Mail", "published_at": "2026-06-11T13:09:17", "published_display": "11 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Cash Burn Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPU1FvM1BvSDE5a0dqQzdUTUFTbWhZWmhnaUNVR1JqTGtyaTdHektINDlpV1Y5d3FNQXhvUTNLMklCV2Y5d3U3YWQwSTZCQ3RPV2o1akw5STNqRk9BN2I0VUdFMzU1T0JJbVR2aEwyamJ0cVFYUVBCYS04WHNFOW16c2djbUJpRDNya21WbkVPaUNfOHJibFE4R1k2d2tIMUV2UnNILTc5bWxFRnRXeHlGcDUzYURhYllfa0JpMEs5UGdZQURmWk9tUDI0eHJuMVhNYW5Faw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Cash Burn Concerns - Consensus Miss Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOb0E2SEh1dXFQU0FJdkl0SG55dERKR0JPOWNPM3V4R3RSOTAwSDROQ1dnS2lWbW5GMlA2YkxYRzI3VG5QS3hKQ3lweWtmSVVrSHgyTU1NNG45TFNacGRBeHpMME56WVpxTDl3TU5QUnNoc0dLQXczcVVaTTNJbHdhTXFkMUFlU0tDRkxrZWMycFhZYndKYmNUek45QzQtR3dDZVVTN2h2dHJOd1RnMWRCOVZmQVVEVVhRb3l3VHZ5T3pydm9jNDZzSl9UMnRUazZNSlJ3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO", "summary": "Telomir Pharmaceuticals has appointed Andriy Mushak as its fractional Chief Financial Officer, effective June 6, following the departure of Alan Weichselbaum. Mushak brings over 20 years of experience in SEC reporting and accounting, and will provide his services through a consul", "url": "https://m.uk.investing.com/news/sec-filings/telomir-pharmaceuticals-appoints-andriy-mushak-as-fractional-cfo-93CH-4718510?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-09T23:09:23", "published_display": "09 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3", "summary": "Telomir Pharmaceuticals (TELO) Chief Financial Officer Andriy Mushak has filed an initial Form 3, an SEC filing that reports his status as an officer. The filing indicates that Mushak does not currently hold any common stock or derivative securities in the company. This Form 3 ac", "url": "https://www.stocktitan.net/sec-filings/TELO/form-3-telomir-pharmaceuticals-inc-initial-statement-of-beneficial-ow-0ed194fcdb51.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:39:39", "published_display": "09 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Names Andriy Mushak as Fractional Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/telomir-names-andriy-mushak-fractional-120714089.html", "source_name": "MT Newswires", "published_at": "2026-06-09T12:07:14+00:00", "published_display": "09 Jun 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com", "summary": "Telomir Pharmaceuticals has appointed Andriy Mushak as its fractional Chief Financial Officer, effective June 6, following Alan Weichselbaum's departure. Mushak, a partner at LMAM Consulting Group, brings over two decades of experience in SEC reporting and accounting. The company", "url": "https://za.investing.com/news/sec-filings/telomir-pharmaceuticals-appoints-andriy-mushak-as-fractional-cfo-93CH-4318895", "source_name": "Investing.com South Africa", "published_at": "2026-06-08T22:39:17", "published_display": "08 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing", "summary": "Telomir Pharmaceuticals announced through an SEC filing that Alan Weichselbaum will step down from his position as CFO, effective June 6, 2026. This brief notice was disseminated via Reuters and is directly related to an SEC filing. The company's stock symbol is TELO.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42G0Z0:0-telomir-pharmaceuticals-alan-weichselbaum-to-step-down-as-cfo-effective-june-6-2026-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-08T21:10:43", "published_display": "08 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO", "summary": "Telomir Pharmaceuticals announced a change in its finance leadership, appointing Andriy Mushak as the new fractional Chief Financial Officer through LMAM Consulting Group, LLC. This follows the departure of Alan Weichselbaum, which the company states was not due to any disagreeme", "url": "https://www.stocktitan.net/sec-filings/TELO/8-k-telomir-pharmaceuticals-inc-reports-material-event-97e9524a656f.html", "source_name": "Stock Titan", "published_at": "2026-06-08T21:10:43", "published_display": "08 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026", "summary": "Telomir Pharmaceuticals, Inc. announced a change in its Chief Financial Officer position, effective June 6, 2026. Alan Weichselbaum is no longer serving as CFO, and Andriy Mushak has been appointed as the Company's fractional Chief Financial Officer. Mr. Mushak is a Certified Pub", "url": "https://www.marketscreener.com/news/telomir-pharmaceuticals-inc-announces-cfo-changes-effective-june-6-2026-ce7f5dd3df8ef125", "source_name": "www.marketscreener.com", "published_at": "2026-06-08T21:10:43", "published_display": "08 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TELO - Telomir Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data and recent news for Telomir Pharmaceuticals Inc (TELO). It details the company's stock performance, key financial metrics, insider ownership, and institutional transactions. The latter part of the article highlights numerous anno", "url": "https://finviz.com/stock?t=TELO", "source_name": "Finviz", "published_at": "2026-05-30T18:12:01", "published_display": "30 May 2026 18:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TELO Stock Price, Quote & Chart | TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO)", "summary": "This article provides a comprehensive overview of TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO) stock, including its current price, performance metrics, and key statistics. It also details the company's technical and fundamental analysis ratings from ChartMill, future earnings dates,", "url": "https://www.chartmill.com/stock/quote/TELO/profile", "source_name": "ChartMill", "published_at": "2026-05-27T04:08:41", "published_display": "27 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider Than Expected Loss Highlights Pre-Revenue Challenges - Dividend Cut Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxONTJDemhDTVdhYmMwZTEyc19UbDFRUGFWRGNjMkxtS2lSY2ZnTVFFSEM0UWY4WG1yaEtaLVNDQ0c3cWFWRVM5NTByMlYtV0lUZ2FkZERoNEk2LTd1a1lSb3hJSTdDMUV5ZS1zV244Y3dPRDNNMEtZSm56bC1QUDFZLWJGOXlvRXNzNlNBXy1aeGhOa0FVTmdfb3ZaM3F3LWJ5SkR1em9zNk5BLU5KV3lVUzBFUmFTb3JURm8xcHBkUnoxbzJOTnMtTkFBMUxuaW5oYUdiZjQ3a1BLWmlTN3FUVVVva08xaFk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir (TELO) director swaps 25K options for new lower-priced grant", "summary": "Telomir Pharmaceuticals director Edward Clouston MacPherson restructured his stock options by canceling an existing grant of 25,000 shares with a $5.02 exercise price and replacing it with a new 25,000-share option at a lower exercise price of $1.30. This transaction, revealed in", "url": "https://www.stocktitan.net/sec-filings/TELO/form-4-telomir-pharmaceuticals-inc-insider-trading-activity-5a2170ba0f4d.html", "source_name": "Stock Titan", "published_at": "2026-05-23T01:39:54", "published_display": "23 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir (NASDAQ: TELO) CEO reshapes 4M+ options at lower $1.30 strike", "summary": "Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov recently modified his stock option awards. He canceled previously granted options totaling nearly 4 million shares at higher exercise prices ($2.10 and $5.02) and received new, fully exercisable options for the same numbe", "url": "https://www.stocktitan.net/sec-filings/TELO/form-4-telomir-pharmaceuticals-inc-insider-trading-activity-19c98654bd8a.html", "source_name": "Stock Titan", "published_at": "2026-05-23T00:10:12", "published_display": "23 May 2026 00:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/telomir-pharmaceuticals-reports-peer-reviewed-120000295.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/telomir-says-us-fda-clears-142611361.html", "source_name": "MT Newswires", "published_at": "2026-04-30T14:26:11+00:00", "published_display": "30 Apr 2026 14:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/telomir-pharmaceuticals-announces-fda-clearance-120000413.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-30T12:00:00+00:00", "published_display": "30 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxON21md2NtM05RZTV3ZkNtY0xpd2tjZlREWEhxb0xNMFgyVHJwQk1seU4zcThUOFBONjRPcVR5SzdCUndqZ0xGbThIeGtQaXFNRWhhMHFKT3d3dVc4RERSUW56eW9xQXJvUlhsOUgwUFVXcWhHZkpfSFNRcHJvR29xUHNBaEhiMk1tOGlPSm9RMnUxaTR0V1A0WTEzYmk3ZnpjSnJCMEppYVJZVDJ0SkV5RFg3a29Lam1iOE9yZERJalNqRUVDc200T0l0R0ZkZEd5R0hNVTlMTmV6MGtpakE5cFNSZ0k?oc=5", "source_name": "ACCESS Newswire", "published_at": "2026-04-24T13:04:25+00:00", "published_display": "24 Apr 2026 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir completes acquisition of TELI Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQSldNNW1ZZThwVlhwejZMZURQekc5ajJKTEZVSVRKSTJ2b0I0d0hyRVNBUlN4d3J0ZHFSR210UnlIOTRoWEtjekQ3UGJxNi1uOUs1LU1Kbm84Z2xCU0l1QmYzSVk1NVo3enlWTTc0VHB3RE5jV1liMTRGVlNDWU05Wlo5ZkVpRmNLOF9NUG1JYW9iLXFBajBTaVBPdWNGYVZZUWNlY1FsVS00MERtSE1z?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQYXJ4ZldVWG9DY2VDd08wMUhHOXdlaTNhYmdyOGhIeUV2Xy1BUFRaOWFEZlBmd1ozTGlVbnJ4Zmp6SDFEZmVvbm5BWVJ6NC16YkZCNEk3NElISzlaN2swYlgxeDBvWFJvR0tOd3poRVVUMmxRVEd1ZjFyeV9GYTJvVzFiQmlwOVhSdENZWURNdWxQaVU3MmJCX2JEcUljaE02VTZkcm0wLWgzcHJUSUhoZFgwRlNhQzN6eXdrUnJhWU5BUHNFbHd2ZHA0bUxtZ01xQ3p2UXI5UHpoYkVVUTY4N1RqU0E?oc=5", "source_name": "ACCESS Newswire", "published_at": "2026-03-31T12:03:01+00:00", "published_display": "31 Mar 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgJBVV95cUxQZFNNVU1oNUNZZ1lLUmJ4cjVqbGRCWlYzTGlvTEg0Q04yZ0Q2UHRHc0U1SjdFbnNTSWR0d0FBZ3k4Q21tbG1yQTBaa29mSElTbFRZcFQwRWx0aGZSTTktUlNmeXI5ZjRRVlJMckJxaFhncVVRajc1MUNxTFBTMHQxSk5vNnRoZ3lUU21nWnN3dHNlVFM1c0FSSWJ4UmRXVkNmMnRyUjV6cGJ3bFkyUFBUTndjS1VsaHdJLW94UnBaRnkzU0ZwVUo4T1VEdzZxLUtrcjc5Q2tEU0dRZ1VYLVRoLTNGU0lWRUFTMVg1OFJ0cDFDeUtfQVZ1NDJxUF9hMHhIQUJ4cUR3?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 68, "sentiment_summary": {"positive": 17, "negative": 8, "neutral": 43, "score": 53, "total": 68, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 22.7, "count": 40}, {"event": "earnings", "label": "Earnings", "weight": 12.05, "count": 22}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 1.23, "latest_week": "2026-07-10", "one_week_move": -3.1, "four_week_move": -2.4, "twelve_week_move": -15.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.26335, "market_dynamics_buy_signal": false, "relative_strength": -24.489192, "fair_value_gap": -63.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.8252, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.1% over one week, -2.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 6}, {"label": "Stock Titan", "count": 6}, {"label": "ACCESS Newswire", "count": 4}, {"label": "dars.gov.et", "count": 3}, {"label": "Barron's", "count": 3}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 60}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Earnings", "count": 22}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "60", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.1% over one week, -2.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?"}], "updated_at": "2026-07-17T17:06:22.724674+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}